This event is not part of the official Scientific Sessions as planned by the AHA Committee on Scientific Sessions Programming.

Activity Description
The management of cardiovascular risk in patients with type 2 diabetes continues to evolve with changing guidelines and emerging data. Accordingly, an online preread activity will provide baseline information with further detail on the evidence-based recommendations for management of cardiovascular risk in patients with type 2 diabetes and the latest data on the long-term cardiovascular outcomes associated with the newest medications to treat type 2 diabetes, including incretin therapies and sodium glucose transporter-2 inhibitors, provided in this workshop. In this activity, participants will have the opportunity to consider the clinical implications of these advances and how they may be incorporated into practice through real-time polling, and the faculty will provide expert commentary on participants’ insights. To conclude the activity, the faculty will guide participants through case studies of complicated cases of patients with diabetes and cardiovascular risk factors to further illustrate incorporation of the newest evidence into clinical practice. Participants will also have the opportunity to participate in an online e-forum following the activity for additional self-directed learning.

Target Audience
The target audience for this educational activity is endocrinologists, cardiologists, primary care clinicians, and other healthcare providers who treat patients and are interested in the primary prevention of cardiovascular disease in patients with diabetes.

Learning Objectives
As a result of participation in this educational activity, participants should be able to:

  1. Apply updated guideline recommendations for the management of cardiovascular risk factors in patients with diabetes.
  2. Summarize existing and emerging evidence of cardiovascular safety of diabetes medications.
  3. Choose optimal, individualized glycemic treatment for patients with diabetes and cardiovascular disease and/or multiple cardiovascular risk factors.

Welcome and Agenda Overview

The Evidence-Based Recommendations for Management of Cardiovascular Risk Factors in Patients With Diabetes
Yehuda Handelsman, MD, FACP, FACE, FNLA

Incretin Therapies and the Sodium Glucose Transporter-2 (SGLT2) Inhibitors: Evidence on Long-Term Cardiovascular Outcomes
Lawrence Blonde, MD, FACP, MACE

Clinical Implications of the Latest Guidelines and Data: Panel Discussion on Audience Insights
Panel Discussion

Case Studies of Patients With Diabetes and Multiple CV Risk Factors/CVD With Discussion
Panel Discussion

Q&A Session and Closing Remarks

Medical Director and President,
Louisville Metabolic and Atherosclerosis Research Center
Louisville, Kentucky

Lawrence Blonde, MD, FACP, MACE
Director, Ochsner Diabetes Clinical Research Unit
Frank Riddick Diabetes Institute
Department of Endocrinology
Ochsner Medical Center
New Orleans, Louisiana

Yehuda Handelsman, MD, FACP, FACE, FNLA
Medical Director and Principal Investigator,
Metabolic Institute of America
Tarzana, California

Accreditation Statement
Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
Forefront Collaborative designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Statement
Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s). The faculty disclosure statements will be listed at the beginning of each slide presentation.

This live activity is provided by Forefront Collaborative and is supported by independent educational grants from Novo Nordisk Inc., Boehringer Ingelheim Pharmaceuticals, Inc., and Lilly USA, LLC.